WO2021150645A1 - Novel cell metabolism modulating compounds and uses thereof - Google Patents

Novel cell metabolism modulating compounds and uses thereof Download PDF

Info

Publication number
WO2021150645A1
WO2021150645A1 PCT/US2021/014250 US2021014250W WO2021150645A1 WO 2021150645 A1 WO2021150645 A1 WO 2021150645A1 US 2021014250 W US2021014250 W US 2021014250W WO 2021150645 A1 WO2021150645 A1 WO 2021150645A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
alkyl
aryl
methyl
acetic acid
Prior art date
Application number
PCT/US2021/014250
Other languages
English (en)
French (fr)
Inventor
Emre Koyuncu
Hahn Kim
Original Assignee
Crescenta Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescenta Biosciences filed Critical Crescenta Biosciences
Priority to CN202180018739.3A priority Critical patent/CN115209883A/zh
Priority to US17/793,670 priority patent/US20230183179A1/en
Priority to KR1020227028856A priority patent/KR20220131536A/ko
Priority to AU2021211437A priority patent/AU2021211437A1/en
Priority to MX2022008938A priority patent/MX2022008938A/es
Priority to BR112022014245A priority patent/BR112022014245A2/pt
Priority to CA3165345A priority patent/CA3165345A1/en
Priority to EP21744382.9A priority patent/EP4093384A1/en
Priority to JP2022544103A priority patent/JP2023518648A/ja
Priority to IL294786A priority patent/IL294786A/en
Publication of WO2021150645A1 publication Critical patent/WO2021150645A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the field of the embodiments of the present invention relate to novel compounds for treatment or prophylaxis of diseases related to metabolism and inflammation, including, but not limited to, type-2 diabetes, atherosclerosis, intracranial atherosclerotic disease, Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, cardiovascular disease, asthma, cancer and other diseases.
  • Compounds in this invention particularly interact with fatty acid binding protein 4 (FABP4) and improve glucose consumption in adipocytes.
  • FABP4 fatty acid binding protein 4
  • Fatty acid binding proteins are a family of proteins that reversibly bind free fatty acids and other lipid molecules and facilitate their transport in cells. To date, nine different FABP isoforms have been identified in mammals. FABP isoforms display differential expression patterns in different tissues. Fatty acid binding protein 4 (FABP4), also often referred to as aP2 in literature, is primarily expressed in adipocytes and macrophages, and mediates key metabolic and inflammatory pathways in these cells, such as lipid storage and degradation, signaling, and eicosanoid production. In addition, FABP4 is also secreted to plasma and has been proposed to act as an adipose-derived factor regulating systemic glucose homeostasis.
  • Fatty acid binding protein 4 FABP4
  • mice bearing a homozygous deletion of the FABP4 gene are subjected to a prolonged high-fat diet, they gained weight comparable to the wild-type, but were protected from hyperglycemia and insulin-resistance. See, G. S. Hotamisligil, et al., “Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in Ap2, the Adipocyte Fatty Acid Binding Protein,” Science, 1996, 274(5291), Pages 1377-9, doi:
  • FABP4-deficiency significantly protected apoliprotein E (ApoE) knockout mice from atherosclerosis, a phenotype attributed to FABP4 modulation of inflammatory pathways in macrophages.
  • ApoE apoliprotein E
  • FABP4 expression has also been detected in airway epithelial cells and FABP4-deficiency was demonstrated to be protective in a mouse model of allergic lung inflammation.
  • triple-negative breast cancer patients with a single nucleotide polymorphism in the 3’ untranslated region (UTR) of FABP4 (rsl054135-GG genotype) that also results in reduced FAB4 expression was associated with a reduced risk of disease progression and a prolonged disease-free survival time.
  • UTR untranslated region
  • FABP4 rsl054135-GG genotype
  • One of their primary roles is taking up excess glucose in plasma and storing it in the form of lipids.
  • FABP4-deficient mice showed increased glucose deposition to adipose tissue.
  • Adipocytes isolated from these animals showed a significantly elevated rate of glucose conversion into fatty acids as compared to their wild-type counterparts. See, S.
  • the present invention in one of its embodiments, relates to a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof: wherein each of R 1 and R 6 -R 9 are independently -H, -CN, -COOH, -CONH 2 , B(OR a ) 2 , an acid isostere, a halo, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl, wherein R a of the B(OR a ) 2 is H or an alkyl, wherein B of the B(OR a ) 2 is boron, wherein n of the C n is 1 - 10, wherein each of R 2 - R 5 are independently -H, -CN, -COOH, -COOMe,
  • the invention comprises the compound of Formula I where at least one of R 1 and R 2 , R 2 and R 3 , R 3 and R 4 , R 4 and R 5 , R 6 and R 7 , R 7 and R 8 , R 8 and R 9 are bonded forming a fused heteroaryl or fused heterocycloalkyl.
  • the invention may be a compound of Formula II or pharmaceutically acceptable salts or esters thereof:
  • R 1 and R 6 -R 9 is independently -H, -CN, -COOH, -CONH 2 , B(OR a ) 2 , an acid isostere, a halo, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl, wherein R a of the B(OR a ) 2 is H or an alkyl, wherein B of the B(OR a ) 2 is boron, wherein n of the C n is 1 — 10, wherein each of R 2 - R 5 are independently -H, -CN, -COOH, -COOMe, -CONH2, B(OR a ) 2 , the acid isostere, the halo, -CONHOH,
  • the invention includes compounds of Formula II, wherein a heterocycloalkyl group is formed by bonding two of R 7 , R 8 , or R 9 to form:
  • R 1 is selected from the group consisting of: -CN, alkyl, -H, halo, 2 H, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxyl-alkyl, hydroxyl-aryl, (aryl)alkyl, C(O)0H, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl, and C(O)NH 2 , wherein each of R 3 and R 4 are independently -H, the halo, C n alkyl, C n alkyl, C n alkenyl, C n
  • Another embodiment of the invention includes compounds of Formula III wherein X is N.
  • An embodiment the invention includes compounds of Formula III wherein R 6 is hydrogen and X is N.
  • a further embodiment the invention includes compounds of Formula III wherein R 3 is alkyl and R 1 is cyano.
  • the pharmaceutical composition can further comprise an additional therapeutically active agent.
  • Such method comprises numerous process steps, such as: administering an effective amount of a compound according to Formula (I), (II) or (III) to a subject in need of such treatment (preferably, a human).
  • the method optionally includes a process step regarding co-administration with other therapeutic agents, either as a single (or multiple) dosing, and either simultaneously or sequentially.
  • disorders include type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, non-alcoholic steatohepatitis, asthma, multiple sclerosis, Alzheimer’s disease, other chronic inflammatory and autoimmune/inflammatory diseases, chronic heart disease, polycystic ovary syndrome, preeclampsia, and cancer.
  • alkyl refers to a saturated, straight-chain hydrocarbon group, or branched- chain hydrocarbon group having from 1 to 20 carbon atoms.
  • Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl- 1 -propyl, 2-methyl-2-propyl,
  • alkoxy refers to an alkyl group singularly bonded to oxygen and includes -O-(alkyl), wherein alkyl is defined above.
  • amino refers to an -NH 2 group.
  • alkenyl refers to a hydrocarbon group formed when a hydrogen atom is removed from an alkene group. Alkenyl compounds are named by replacing the -e from the parent alkene's name with -yl.
  • haloalkyl refers to any alkyl radical having one or more hydrogen atoms replaced by a halogen atom.
  • phenyl refers to a univalent hydrocarbon radical (C 6 H 5 ) formally derived from benzene by the removal of a hydrogen atom.
  • naphthyl refers to an isomeric univalent radical formally derived from naphthalene by removal of a hydrogen atom.
  • pyrrole refers to a heterocyclic aromatic organic compound that is a five- membered ring with the formula C 4 H 4 NH.
  • imidazole refers to an organic compound with the formula C 3 N 2 H 4 .
  • thiophene refers to a heterocyclic compound with the formula C 4 H 4 S.
  • furan refers to a heterocyclic organic compound consisting of a five- membered aromatic ring with four carbon atoms and one oxygen.
  • thiazole refers to a heterocyclic compound that contains both sulfur and nitrogen and contains the molecular formula C 3 H 3 NS.
  • isothiazole or 1,2-thiazole refers to an organic compound containing a five- membered aromatic ring that consists of three carbon atoms, one nitrogen atom, and one sulfur atom.
  • thiadiazole refers to a sub-family of azole compounds, that are five- membered heterocyclic compounds containing one sulfur and two nitrogen atoms.
  • oxazole refers to the parent compound for a class of heterocyclic aromatic organic compounds. Oxazoles are azoles with an oxygen and a nitrogen separated by one carbon.
  • isoxazole refers to an azole with an oxygen atom next to the nitrogen.
  • oxadiazole refers to a class of heterocyclic aromatic chemical compounds of the azole family with the molecular formula C 2 H 2 N 2 O.
  • pyridine refers to a basic heterocyclic organic compound with the chemical formula C 5 H 5 N. Pyridine is structurally related to benzene, with one methine group replaced by a nitrogen atom.
  • pyrazine refers to a heterocyclic organic compound with the chemical formula C4H4N2. Pyrazine is less basic than pyridine, pyridazine and pyrimidine.
  • pyrimidine refers to a heterocyclic organic compound similar to pyridine.
  • One of the three diazines, pyrimidine has the nitrogen atoms at positions 1 and 3 in the ring.
  • pyridazine is a heterocyclic organic compound with the molecular formula (CH) 4 N 2.
  • Pyrimidine contains a six-membered ring with two adjacent nitrogen atoms.
  • pyrazole refers to an organic compound with the formula C 3 H 3 N2H. Pyrazole is a heterocycle characterized by a 5-membered ring of three carbon atoms and two adjacent nitrogen atoms.
  • trizole refers to any of the heterocyclic compounds with molecular formula C2H 3 N 3 , having a five-membered ring of two carbon atoms and three nitrogen atoms.
  • tetrazole refers to a class of synthetic organic heterocyclic compounds, consisting of a 5-member ring of four nitrogen atoms and one carbon atom.
  • the name tetrazole also refers to the parent compound with formula CH 2 N 4 .
  • chroman or “chromane” refers to a heterocyclic chemical compound with the chemical formula C 9 H 10 O.
  • quinoline refers to a heterocyclic organic compound with the chemical formula C 9 H 7 N.
  • quinoxaline or “benzopyrazine” refers to a heterocyclic compound containing a ring complex made up of a benzene ring and a pyrazine ring.
  • isoquinoline refers to a heterocyclic aromatic organic compound.
  • Isoquinoline is a structural isomer of quinoline.
  • Isoquinoline and quinoline are benzopyridines, which are composed of a benzene ring fused to a pyridine ring.
  • phthalazine “benzo-orthodiazine,” or “benzopyridazine” is a heterocyclic organic compound with the molecular formula C 8 H 6 N 2 . It is isomeric with other naphthyridines, including quinoxaline, cinnoline and quinazoline.
  • chromenoline is a heterocyclic compound with the formula C 8 H 6 N 2 . It is isomeric with other naphthyridines, including quinoxaline, phthalazine and quinazoline.
  • Quinazoline refers to an organic compound with the formula C 8 H 6 N 2 .
  • Quinazoline is a heterocycle with a bicyclic structure consisting of two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.
  • Indole is a heterocyclic organic compound with formula C 8 H 7 N. Indole has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered pyrrole ring.
  • isoindole is a benzo-fused pyrrole and is an isomer of indole.
  • Indoline is a heterocyclic organic compound with the chemical formula C 8 H 9 N. Indoline has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.
  • isoindoline refers to a heterocyclic organic compound with the molecular formula C 8 H 9 N.
  • the parent compound has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.
  • benzothiophene refers to an organic compound with a molecular formula
  • benzofuran refers to a heterocyclic compound consisting of fused benzene and furan rings.
  • isobenzofuran refers to a heterocyclic compound consisting of fused benzene and furan rings. Isobenzofuran is isomeric with benzofuran.
  • benzoxazole refers to an organic compound with a molecular formula C 7 H 5 NO and includes a benzene-fused oxazole ring structure.
  • benzothi azole refers to a heterocyclic compound with the chemical formula C 7 H 5 NS.
  • benzimidazole refers to a heterocyclic organic compound. Benzimidazole is a bicyclic compound that consists of the fusion of benzene and imidazole.
  • indazole or isoindazole refers to a heterocyclic organic compound that consists of the fusion of benzene and pyrazole.
  • benzodioxane refers to isomeric chemical compounds with the molecular formula C 8 H 8 O 2 .
  • indane or “indan” refers to an organic compound with the formula C 6 H 4 (CH 2 ) 3
  • acridine refers to an organic compound and a nitrogen heterocycle with the formula C 13 H 9 N.
  • Acridines are substituted derivatives of the parent ring. It is a planar molecule that is structurally related to anthracene with one of the central CH groups replaced by nitrogen.
  • Phenazine refers to an organic compound with the formula (C 6 H 4 ) 2 N 2 . Phenazine is a dibenzo annulated pyrazine.
  • xanthene refers to an organic compound with the formula CH 2 [C 6 H 4 ] 2 O.
  • isochroman refers to a compound having the formula C 9 H 10 O and the following structure:
  • 2,1,3-benzoxadiazole refers to an organic compound having the following structure:
  • 2,1,3-benzothiazole refers to a heterocyclic compound with the chemical formula C 7 H 5 NS.
  • 2,1,3-benzoselenadiazole refers to an organic compound having the following structure:
  • tetrahydroquinoline refers to an organic compound that is the semi- hydrogenated derivative of quinoline.
  • 1,5- naphthyridine refers to an organic compound having the following structure:
  • 1,8-naphthyridine refers to an organic compound with the formula C 8 H 6 N 2 .
  • aryl means a monocyclic, bicyclic, or tricyclic aromatic group, wherein all rings of the group are aromatic and all ring atoms are carbon atoms. For bicyclic or tricyclic systems, the individual aromatic rings are fused to one another. Examples of aryl groups are 6 and 10 membered aryls. Further examples of aryl groups include, but are not limited to, phenyl, naphthalene, and anthracene.
  • cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
  • deuterium as used herein means a stable isotope of hydrogen having one proton and one neutron.
  • halogen refers to fluorine, chlorine, bromine, iodine, astatine, or tennessine.
  • halo represents a group comprising a halogen.
  • hydroxy means an -OH group.
  • N-oxide refers to the oxidized form of a nitrogen atom.
  • cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, bridged polycyclic, or spiro polycyclic carbocycle having from 3 to 15 carbon ring atoms.
  • a non-limiting category of cycloalkyl groups are saturated or partially saturated, monocyclic carbocycles having from 3 to 6 carbon atoms.
  • Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
  • heterocycloalkyl refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated or partially saturated and has from three to 12 ring atoms selected from carbon atoms and up to three heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the ring structure may optionally contain up to two oxo groups on carbon or sulfur ring members, or an N-oxide.
  • Illustrative heterocycloalkyl entities include, but are not limited to the following:
  • heteroaryl refers to a monocyclic, or fused polycyclic, aromatic heterocycle having from three to 15 ring atoms that are selected from carbon, oxygen, nitrogen, and sulfur. Suitable heteroaryl groups do not include ring systems that must be charged to be aromatic, such as pyrylium. Suitable 5-membered heteroaryl rings (as a monocyclic heteroaryl or as part of a polycyclic heteroaryl) have one oxygen, sulfur, or nitrogen ring atom, or one nitrogen plus one oxygen or sulfur, or 2, 3, or 4 nitrogen ring atoms.
  • Suitable 6-membered heteroaryl rings (as a monocyclic heteroaryl or as part of a polycyclic heteroaryl) have 1, 2, or 3 nitrogen ring atoms.
  • heteroaryl groups include, but are not limited to, pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl
  • fused heteroaryl refers to a heteroaryl as defined above, having two constituent aromatic rings, wherein the two rings are fused to one another and at least one of the rings is a heteroaryl as defined above.
  • Fused heteroaryls include fused heteroaryl groups comprising 1, 2, 3, or 4 heteroatom ring atoms selected from O, N or S. In certain embodiments, wherein the heteroatom is N it can be an N-oxide.
  • Fused heteroaryls also include 8-, 9-, or 10- membered fused heteroaryl groups.
  • Fused heteroaryls also include 8-, 9-, or 10-membered fused heteroaryl groups that have 1, 2, 3, or 4 heteroatom ring atoms selected from O, N or S.
  • fused heteroaryls include, but are not limited to, the following:
  • liquid chromatography-mass spectrometry or LC-MS is an analytical chemistry technique that combines the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis capabilities of mass spectrometry (MS).
  • proto nuclear magnetic resonance or 1H NMR is the application of nuclear magnetic resonance in NMR spectroscopy with respect to hydrogen- 1 nuclei within the molecules of a substance, in order to determine the structure of its molecules.
  • substituted means that the specified group or moiety bears one or more suitable substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by the specified number of substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
  • substituted refers to an atom or group of atoms that replaces one or more hydrogen atoms on the parent chain of a hydrocarbon, becoming a moiety of the resultant new molecule.
  • Any atom that is represented herein with an unsatisfied valence is assumed to have the sufficient number of hydrogen atoms to satisfy the atom’s valence.
  • variable e.g., alkyl, R a , R 1 , etc.
  • the definition of that variable on each occurrence is independent of its definition at every other occurrence.
  • Numerical ranges are intended to include sequential whole numbers. For example, a range expressed as “from 0 to 4” or “0-4” includes 0, 1, 2, 3 and 4.
  • the point of attachment to the remainder of the formula can be at any point on the multifunctional moiety.
  • the point of attachment is indicated by a line or hyphen.
  • aryloxy- refers to a moiety in which an oxygen atom is the point of attachment to the core molecule while aryl is attached to the oxygen atom.
  • the term “subject” encompasses mammals and non-mammals.
  • mammals include, but are not limited to, any member of the Mammalian class, such as: humans, non-human primates (e.g., chimpanzees, apes, and monkey species), farm animals (e.g., cattle, horses, sheep, goats, swine, etc.), domestic animals (e.g., rabbits, dogs, cats, etc.), and laboratory animals (e.g., rodents, such as rats, mice and guinea pigs, and the like).
  • non-mammals include, but are not limited to, birds, fish, and the like.
  • the mammal is a human.
  • patient or “subject” includes both human and animals.
  • an “effective amount” or “therapeutically effective amount” refer to a sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease or medical condition, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic use is the amount of a compound, or of a composition comprising the compound, that is required to provide a clinically relevant change in a disease state, symptom, or medical condition.
  • An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • the expression “effective amount” generally refers to the quantity for which the active substance has a therapeutically desired effect.
  • the terms “treat” or “treatment” encompass both “preventative” and “curative” treatment.
  • the phrase “preventative treatment” is meant to indicate a postponement of development of a disease, a symptom of a disease, or medical condition, suppressing symptoms that may appear, or reducing the risk of developing or recurrence of a disease or symptom.
  • the phrase “curative treatment” refers to reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition.
  • treatment includes ameliorating or preventing the worsening of existing disease symptoms, preventing additional symptoms from occurring, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
  • the present invention in one of its embodiments, relates to a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof:
  • each of R 1 and R 6 -R 9 are independently -H, -CN, -COOH, -CONH 2 , B(OR a ) 2 , an acid isostere, a halo, C n alkyl, C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl, wherein R a of the B(OR a ) 2 is H or an alkyl, wherein B of the B(OR a ) 2 is boron, wherein n of C n is 1 - 10, wherein each of R 2 - R 5 are independently -H, -CN, -COOH, -COOMe, -CONH2, B(OR a ) 2 , the acid isostere, the halo, -CONHOH, -
  • the invention comprises the compound of Formula I where at least one of R 1 and R 2 are bonded forming a fused heteroaryl.
  • the invention comprises the compound of Formula I where at least one of R 2 and R 3 are bonded forming a fused heteroaryl. In one embodiment, the invention comprises the compound of Formula I where at least one of R 3 and R 4 are bonded forming a fused heteroaryl.
  • the invention comprises the compound of Formula I where at least one of R 4 and R 5 are bonded forming a fused heteroaryl.
  • the invention comprises the compound of Formula I where at least one of R 5 and R 6 are bonded forming a fused heteroaryl.
  • the invention comprises the compound of Formula I where at least one of R 6 and R 7 are bonded forming a fused heteroaryl.
  • the invention comprises the compound of Formula I where at least one of R 7 and R 8 are bonded forming a fused heteroaryl.
  • the invention comprises the compound of Formula I where at least one of R 8 and R 9 are bonded forming a fused heteroaryl.
  • the invention comprises the compound of Formula I where at least one of R 1 and R 2 are bonded forming a fused heterocycloalkyl.
  • the invention comprises the compound of Formula I where at least one of R 2 and R 3 are bonded forming a fused heterocycloalkyl.
  • the invention comprises the compound of Formula I where at least one of R 3 and R 4 are bonded forming a fused heterocycloalkyl.
  • the invention comprises the compound of Formula I where at least one of R 4 and R 5 are bonded forming a fused heterocycloalkyl.
  • the invention comprises the compound of Formula I where at least one of R 5 and R 6 are bonded forming a fused heterocycloalkyl.
  • the invention comprises the compound of Formula I where at least one of R 6 and R 7 are bonded forming a fused heterocycloalkyl.
  • the invention comprises the compound of Formula I where at least one of R 7 and R 8 are bonded forming a fused heterocycloalkyl.
  • the invention comprises the compound of Formula I where at least one of R 8 and R 9 are bonded forming a fused heterocycloalkyl.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, and where R 3 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is -H, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is -CN, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is -COOH, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is -CONH 2 , and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is B(OR a ) 2 , where B of B(OR a ) 2 is boron, where Ra of B(OR a ) 2 is H, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is B(OR a ) 2 , where B of B(OR a ) 2 is boron, where R a of B(OR a ) 2 is an alkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is an acid isostere as disclosed herein, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a halo, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl, where n of the C n alkyl is 1 - 10, where the C n alkyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl, where n of the C n alkyl is 1 - 10, where the C n alkyl is substituted with 1 substituent, where the substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl, where n of the C n alkyl is 1 - 10, where the C n alkyl is substituted with 2-5 substituents, where the substituents are the same, and where each of the substituents is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alky
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl, where n of the C n alkyl is 1 - 10, where the C n alkyl is substituted with 2-5 substituents, where the substituents differ, where each of the substituents is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n alkyl is 1 - 10, where a quantity of the substituents is 1, where the substituent is H, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is 2 H, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a halo, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an amino group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an alkoxy group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a cyano group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an aminoalkyl-, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an (amino)alkoxy-, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkyl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkenyl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkynyl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an alkoxy- group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a hydroxy group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkylhydroxy group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an aryloxy- group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkyl(aryl) group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an (alkoxyalkyl)amino- group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an aryl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an -aryl(halo) group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a -heteroaryl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a hydroxyl-alkyl- group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a hydroxyl-aryl- group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is an (aryl)alkyl- group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a -S(O) 2 -alkyl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a -S(O) 2 -aryl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is a -C(O)alkyl group, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is aryl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is heteroaryl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where the n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is cycloalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is heterocycloalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is O, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is S, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is SO 2 , and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n alkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n alkenyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n alkynyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U- C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n aryl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n aminoalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n haloalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n heteroaryl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n cycloalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently the C n heterocycloalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of the C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 )
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 )
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n is 1 - 10, where a quantity of the substituents is 1, where the substituent is -C q -U-C q , where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 )
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are the same, where each of the substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are different, where each of the substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are the same, where each of the substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are different, where each of the substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is heteroaryl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is cycloalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is heterocycloalkyl, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is O, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is S, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is SO 2 , and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and where R 2 - R 5 , W
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, each R 1 of N(R 1 )(
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, each R 1 of N(R 1 )(
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -C q -U-C q , wherein each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), wherein each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, each R 1 of N(R 1 )(
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -al
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl,
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 ofN(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q.
  • each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 2-5 substituents that differ and may include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, al
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl,
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 2-5 substituents that differ and may include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alky
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q.
  • each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 2-5 substituents that differ and may include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, al
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 2-5 substituents that differ and may include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, - alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q - U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q - U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q - U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q - U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl where n of C n is 1 - 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alky
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q.
  • each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q, where each q of - C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl where n of C n is 1 - 10, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoaryl, where n of C n is 1 - 10, where the C n alkenyl is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alky
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is unsubstituted, and where R 2 - R 5 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1 substituent comprising: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 2-5 substituents that are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 1 substituent, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 ofN(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 2-5 substituents that differ and may include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, al
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl, where n of C n is 1 - 10, where the C n alkenyl is substituted with 2-5 substituents, where at least one of the substituents is -C q -U-C q, where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoal
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, each of R 2 - R 5 are independently -H, -CN, -COOH, -COOMe, -CONH2, B(OR a )2, the acid isostere, the halo, -CONHOH, -NH-SO 2 -C 1 -C 6 -alkyl, -NHSO 2 Ar, the C n alkyl, the C n alkyl, the C n alkenyl, the C n alkynyl, the C n aryl, the C n aminoalkyl, the C n haloalkyl, the C n heteroaryl, the C n cycloalkyl, or the C n heterocycloalkyl, where the B of B(OR a )2 is Boron, where the R a of B(OR a ) 2 is H or alkyl, and
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where the Ar of -NHSO 2 Ar is selected from the group consisting of: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is naphthyl, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrrole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is imidazole, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is thiophene, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isothiazole, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is thiadiazole, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is oxazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoxazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is oxadiazole, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyridine, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrazine, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrimidine, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyridazine, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is triazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is tetrazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is chroman, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isochroman, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is quinoline, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is quinoxaline, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoquinoline, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is phthalazine, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is cinnoline, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is quinazoline, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indole, and where R 1 , R 6 -R 9 ,
  • W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoindole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indoline, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoindoline, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzothiophene, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzofuran, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isobenzofuran, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzoxazole, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 2,1,3-benzoxadiazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzothi azole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 2,1,3-benzothiazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 2,1,3-benzoselenadiazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzimidazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indazole, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzodioxane, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indane, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 1,2,3,4-tetrahydroquinoline, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 3,4-dihydro-2H-l,4- benzoxazine, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 1,5- naphthyridine, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 1,8-naphthyridine, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is acridine, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is phenazine, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is xanthene, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl that is unsubstituted, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl that is substituted with 1 substituent, where n of C n is 1 - 10, where the substituent is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl that is substituted with 1 substituent, where n of C n is 1 - 10, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , and N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl that is substituted with 1 substituent, where n of C n is 1 - 10, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is unsubstituted and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl that is substituted with 1 substituent, where n of C n is 1 - 10, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents that are the same, where the substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl),
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is C n alkenyl, C n alkynyl, C n aryl, C n aminoalkyl, C n haloalkyl, C n heteroaryl, C n cycloalkyl, or C n heterocycloalkyl that is substituted with 1 substituent, where n of C n is 1 - 10, where the substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents that differ, where each of the 1-5 substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(ary
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where the quantity of substituents is 1, where the substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, or -C(O)alkyl
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where the quantity of substituents is 2-5, where each of the substituents is the same and is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, or
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where the quantity of substituents is 2-5, where each of the substituents differs and is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl, or
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where the quantity of substituents is 1, where the substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where the quantity of substituents is 1, where the substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 1, where the substituent is -C q -U-C q, , where each q of -C q - U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is unsubstituted, and where R 1 , R 6 -
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 1, where the substituent is -C q -U-C q, , where each q of -C q - U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where each of the 1-5 substituent
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkenyl that is unsubstituted, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkenyl that is substituted with 1-5 substituents, where n of C n is 1 - 10, where each of the substituents are the same or different and include H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkenyl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 2-5, where each at least one of the substituents is -C q -U- C q.
  • each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where the substituent of each R 1 of N(R 1 )(R 1 ) is the same or different and are independently selected from the group consisting of H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl that is substituted with 1-5 substituents that are the same or are different, where n of C n is 1 - 10, where the substituent(s) is/are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 1-5, where the substituent(s) is/are -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl, where n of C n is 1 - 10, and where R 1 , R 6 - R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl that is unsubstituted, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 1-5, where the substituent(s) are the same or are different, where each of the substituent(s) is/are: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 1-5, where at least one the substituents is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where the substituent of each R 1 of N(R 1 )(R
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl, where n of the C n is 1 — 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl that is unsubstituted, where n of the C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl that is substituted with 1-5 substituents, where n of the C n is 1 — 10, where each of the substituents is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, - alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl that is substituted, where n of the C n is 1 - 10, where the quantity of substituents is 1-5, where at least one of the substituents is -C q - U-C q, , where each q of -C q -U-C q is independently 0 to 10, where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where the substituent of each R 1 of N(R 1
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl that is unsubstituted, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl that is substituted with 1-5 substituents, where n of C n is 1 - 10, where each of the substituents is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 1-5, where at least one of the substituents is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where the substituent of each R 1 of N(R 1
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl that is unsubstituted, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl that is substituted with 1-5 substituents, where n of C n is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -aryl,
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl that is substituted, where n of C n is 1 - 10, where the quantity of substituents is 1-5, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where the substituent
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl that is unsubstituted, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl that is substituted with 1-5 substituents, where n of C n is 1 - 10, where each of the substituents is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, - alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl that is substituted, where n of C n is 1 - 10, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where the substituent of each R 1 of N(R 1
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl that is unsubstituted, where n of C n is 1 - 10, and where R 1 , R 6 -R 9 , W, T, Y, Z, Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl that is substituted with 1-5 substituents, where n of C n is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O) 2 -ary
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl that is substituted with 1-5 substituents, where n of C n is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents, where the substituent of each
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Q is a bond, and where R 1 - R 9 , W, T, Y, Z, and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Q is O, and where R 1 - R 9 , W, T, Y, Z, and X are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is C, and where R 1 - R 9 , W, T, Y, Z, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is N, and where R 1 - R 9 , W, T, Y, Z, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is O, R 6 is not present, and where R 1 - R 5 , R 7 - R 9 , W, T, Y, Z, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is S, R 6 is not present, and where R 1 - R 5 , R 7 - R 9 , W, T, Y, Z, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where A is unsaturated, and where R 1 - R 9 , W, T, Y, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where A is saturated, and where R 1 - R 9 , W, T, Y, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a bond, and where R 1 - R 9 , W, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a C, and where R 1 - R 9 , W, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a N, and where R 1 - R 9 , W, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a O, and where R 1 - R 9 , W, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a an alkyl having 1 to 4 carbon atoms, and where R 1 - R 9 , W, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a an alkenyl having 1 to 4 carbon atoms, and where R 1 - R 9 , W, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a C, and where R 1 - R 9 , W, Y, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a N, and where R 1 - R 9 , W, Y, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a O, and where R 1 - R 9 , W, Y, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a an alkyl having 1 to 4 carbon atoms, and where R 1 - R 9 , W, Y, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a an alkenyl having 1 to 4 carbon atoms, and where R 1 - R 9 , W, Y, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a C, and where R 1 - R 9 , Y, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a N, and where R 1 - R 9 , Y, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a O, and where R 1 - R 9 , Y, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a an alkyl having 1 to 4 carbon atoms, and where R 1 - R 9 , Y, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a an alkenyl having 1 to 4 carbon atoms, and where R 1 - R 9 , Y, T, Z, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a bond, and where R 1 - R 9 , W, T, Y, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a C, and where R 1 - R 9 , W, T, Y, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a N, and where R 1 - R 9 , W, T, Y, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a an alkyl having 1 to 4 carbon atoms, and where R 1 - R 9 , W, T, Y, X, and Q are as defined.
  • An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a an alkenyl having 1 to 4 carbon atoms, and where R 1 - R 9 , W, T, Y, X, and Q are as defined.
  • the invention may be a compound of Formula II or pharmaceutically acceptable salts or esters thereof: wherein R 1 and R 6 -R 9 is independently -H, -CN, -COOH, -CONH 2 , B(OR a ) 2 , an acid isostere, a halo, C n alkyl, C n alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein the halo is selected from the group consisting of -F, -Cl, -Br, -I, -At, and -Ts, wherein the R a is H or an alkyl, wherein the B is boron, wherein n is 1 - 10, wherein each of R 2 - R 5 are independently -H, -CN, -COOH, -COOMe, -COMB, B(
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is -CN, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is -COOH, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is -CONH 2 , and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is B(OR a ) 2 , where B of B(OR a )2 is boron, where R a of B(OR a ) 2 is H, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is an acid isostere as disclosed herein, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a halo, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted with 1-5 substituents, where n of C n alkyl is 1 - 10, where each substituent is the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is H, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is 2 H, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an amino group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is a cyano group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an aminoalkyl-, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an -alkyl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an -alkenyl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an -alkynyl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an alkoxy- group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is a hydroxy group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an - alkylhydroxy group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an aryloxy- group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an - alkyl(aryl) group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is an (alkoxyalkyl)amino- group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an aryl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is an - aryl(halo) group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - heteroaryl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a hydroxyl-alkyl- group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a hydroxyl-aryl- group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is an (aryl)alkyl- group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - S(O) 2 -alkyl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - S(O) 2 -aryl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - C(O)alkyl group, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is heteroaryl, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is cycloalkyl, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is heterocycloalkyl, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is O, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is S, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is SO 2 , and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is unsubstit
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted, where n of C n alkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -C q -U-C q , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n alkyl is 1 - 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n alkenyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of C n alkenyl is 1 - 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aryl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of C n aryl is 1 - 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n aminoalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of C n aminoalkyl is 1 - 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n haloalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of C n haloalkyl is 1 — 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heteroaryl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of C n heteroaryl is 1 — 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n cycloalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of C n cycloalkyl is 1 - 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 1 and R 6 -R 9 is a C n heterocycloalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of C n heterocycloalkyl is 1 - 10, and where R 2 - R 5 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -H, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -CN, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -COOH, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -COOMe, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -CONH 2 , and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is B(OR a ) 2 , where B is boron, where R a is H, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is B(OR a ) 2 , where B is boron, where R a is an alkyl, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the acid isostere, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the halo, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -CONHOH, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NH- SO 2 -C 1 -C 6 -alkyl, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is phenyl, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is naphthyl, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrrole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is imidazole, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is thiophene, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isothiazole, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is thiadiazole, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is oxazole, and where R 1 , R 6 -R 9 ,
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoxazole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is oxadiazole, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyridine, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrazine, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrimidine, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyridazine, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is pyrazole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is triazole, and where R 1 , R 6 -R 9 ,
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is tetrazole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is chroman, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isochroman, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is quinoline, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is quinoxaline, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoquinoline, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is phthalazine, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is cinnoline, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is quinazoline, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoindole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indoline, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isoindoline, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzothiophene, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzofuran, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is isobenzofuran, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzoxazole, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 2,1,3-benzoxadiazole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzothi azole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 2,1,3-benzothiazole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzimidazole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indazole, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is benzodioxane, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is indane, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 1,2,3,4-tetrahydroquinoline, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 3,4-dihydro-2H-l,4- benzoxazine, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is 1,8-naphthyridine, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is acridine, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is phenazine, and where R 1 , R 6 - R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is -NHSO 2 Ar, where Ar is xanthene, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is unsubstituted, where n is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where the quantity of substituents is 1-5, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), where n of C n alkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where n of C n alkyl is 1 — 10, where the quantity of substituents is 1-5, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is unsubstituted, and where
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkyl that is substituted, where n of C n alkyl is 1 — 10, where the quantity of substituents is 1-5, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )(R 1 ) is substituted with 1-5 substituents that
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkenyl that is unsubstituted, where n of C n alkenyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkenyl that is substituted, where n of C n alkenyl is 1 - 10, where the quantity of substituents is 1-5 that are the same or are different, where each substituted is: H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkenyl that is substituted with 1-5 substituents, where n of C n alkenyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q - U-C q is independently 0 to 10, where the U of -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkenyl that is substituted with 1-5 substituents, where n of C n alkenyl is 1 - 10, where at least one substituent is -C q -U-C q.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl, where n of C n alkynyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl that is unsubstituted, where n of C n alkynyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl that is substituted with 1-5 substituents that are the same or are different, where n of C n alkynyl is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl that is substituted, where n of the C n alkynyl is 1 - 10, where the quantity of substituents is 1-5, where each substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n alkynyl that is substituted, where n of the C n alkynyl is 1 - 10, where the quantity of substituents is 1-5, where each substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl that is unsubstituted, where n of C n aryl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl that is substituted with 1-5 substituents that are the same or are different, where n of C n aryl is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl that is substituted with 1-5 substituents that are the same or are different, where n of C n aryl is 1 - 10, where at least one substituent is -C q - U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aryl that is substituted with 1-5 substituents that are the same or are different, where n of C n aryl is 1 - 10, where at least one substituent is -C q - U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl, where n of C n aminoalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl that is unsubstituted, where n of C n aminoalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n aminoalkyl is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n aminoalkyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , orN(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n aminoalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n aminoalkyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl, where n of C n haloalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl that is unsubstituted, where n of C n haloalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n haloalkyl is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alky
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n haloalkyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n haloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n haloalkyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl, where n of the C n heteroaryl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl that is unsubstituted, where n of the C n heteroaryl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl that is substituted with 1-5 substituents that are the same or are different, where n of C n heteroaryl is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl that is substituted with 1-5 substituents that are the same or are different, where n of C n heteroaryl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q - U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heteroaryl that is substituted with 1-5 substituents that are the same or are different, where n of C n heteroaryl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q - U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of N(R 1 )
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl, where n of C n cycloalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl that is unsubstituted, where n of C n cycloalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n cycloalkyl is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alky
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n cycloalkyl is 1 - 10, where at least one substituent is -C q -U-C q.
  • each q of -C q -U-C q is independently 0 to 10
  • the U of -C q - U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n cycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n cycloalkyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q - U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1 of
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl, where n of the C n heterocycloalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl that is unsubstituted, where n of the C n heterocycloalkyl is 1 - 10, and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of C n heterocycloalkyl is 1 - 10, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl that is substituted with 1-5 subsistent that are the same or are different, where n of C n heterocycloalkyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO 2 , or N(R 1 )(R 1 ), and where R 1 , R 6 -R 9 , Q and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R 2 - R 5 is the C n heterocycloalkyl that is substituted with 1-5 subsistent that are the same or are different, where n of C n heterocycloalkyl is 1 - 10, where at least one substituent is -C q -U-C q, , where each q of -C q -U-C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, the C n alkyl, the C n alkenyl, the C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R 1
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Q is a bond, and where R 1 - R 9 and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is C, and where R 1 - R 9 and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is N, and where R 1 - R 9 , R 1 - R 9 and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is O, R 6 is not present, and where R 1 - R 5 , R 7 - R 9 , R 1 - R 9 and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is S, R 6 is not present, and where R 1 - R 5 , R 7 - R 9 , R 1 - R 9 and X are as defined.
  • An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 - 3, and where R 1 - R 9 , Q and X are as defined.
  • R 1 is selected from the group consisting of: -CN, alkyl, -H, halo, 2 H, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxyl-alkyl, hydroxyl-aryl, (aryl)alkyl, C(O)OH, -S(O) 2 -alkyl, -S(O) 2 -aryl, -C(O)alkyl, and C(O)NH 2 , wherein each of R 3 and R 4 are independently -H, the halo, C n alkyl, C n alkyl, the C n alkenyl
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0, and where R 1 , R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 1, and where R 1 , R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Q is a bond, and where R 1 , R 3 -R 4 , R 6 -R 8 , X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Q is O, and where R 1 , R 3 -R 4 , R 6 -R 8 , X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is C, and where R 1 , R 3 -R 4 , R 6 -R 8 , Q, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is N, and where R 1 , R 3 -R 4 , R 6 -R 8 , Q, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is O, where R 6 is not present, and where R 1 , R 3 -R 4 , R 7 -R 8 ,
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is S, where R 6 is not present, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z 1 is C, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z 1 is N, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z 1 is O, and where R 1 , R’-R 4 , R 7 -R 8 , Q, X, and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z 1 is S, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W 1 is C, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, and Z 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W 1 is N, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, and Z 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W 1 is O, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, and Z 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W 1 is S, and R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, and Z 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is -CN, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is alkyl, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is -H, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is a halo, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is 2 H, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an amino group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an alkoxy group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an aminoalkyl group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an (amino)alkoxy group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an alkynyl group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an alkoxy group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is a hydroxy group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an alkylhydroxy group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an aryloxy group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an alkyl(aryl) group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an (alkoxyalkyl)amino group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an aryl group, and where R’-R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an aryl(halo) group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is a heteroaryl group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is a hydroxyl-alkyl group, and where R 3 -R 4 , R 6 -R 8 , Q, X,
  • Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is a hydroxyl-aryl group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is an (aryl)alkyl group, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is C(O)OH, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is -S(O) 2 -alkyl, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is -S(O) 2 -aryl, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is C(O)alkyl, and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R 1 is C(O)NH 2 , and where R 3 -R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is -H, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a halo, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkyl, where the n of the C n alkyl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkyl, where the C n alkyl is unsubstituted, where the n of the C n alkyl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkenyl, where the C n alkenyl is unsubstituted, where the n of the C n alkenyl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkynyl, where the C n alkynyl is unsubstituted, where the n of the C n alkynyl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n aryl, where the C n aryl is unsubstituted, where the n of the C n aryl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n aminoalkyl, where the C n aminoalkyl is unsubstituted, where the n of the C n aminoaryl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n haloalkyl, where the C n haloalkyl is unsubstituted, where the n of the C n haloalkyl is 1 - 10, and where R 1 , R 4 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n heteroaryl, where the C n heteroaryl is unsubstituted, where the n of the C n heteroaryl is 1 - 10, and where R 1 , R 6 -R 8 , Q,
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n cycloalkyl, where the C n cycloalkyl is unsubstituted, where the n of the C n cycloalkyl is 1 - 10, and where R 1 , R 6 -R 8 , Q,
  • X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n heterocycloalkyl, where the C n heterocycloalkyl is unsubstituted, where the n of the C n heterocycloalkyl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is -C q -U-C q , and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is -C q -U-C q , where each q of -C q -U- C q is independently 0 to 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is -C q -U-C q , where each q of -C q -U- C q is independently 0 to 10, where the U of -C q -U-C q is O, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is -C q -U-C q , where each q of -C q -U- C q is independently 0 to 10, where the U of -C q -U-C q is S, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is -C q -U-C q , where each q of -C q -U- C q is independently 0 to 10, where the U of -C q -U-C q is SO 2 , and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 and R 4 is -C q -U-C q , where each q of -C q -U- C q is independently 0 to 10, where the U of -C q -U-C q is N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) is independently hydrogen, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkyl, where the C n alkyl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkenyl, where the C n alkenyl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkynyl, where the C n alkynyl is unsubstituted, where the n of the C n alkynyl is 1 - 10, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n alkynyl, where the C n alkynyl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n aryl, where the C n aryl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -S(O
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n aminoalkyl, where the C n aminoalkyl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl,
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n haloalkyl, where the C n haloalkyl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n heteroaryl, where the C n heteroaryl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -alkyl, -
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n cycloalkyl, where the C n cycloalkyl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is a C n heterocycloalkyl, where the C n heterocycloalkyl is substituted with 1-5 substituents that are the same or different, where each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O) 2 -
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where at least one of R 3 andR 4 is -C q -U-C q , where each q of -C q -U- C q is independently 0 to 10, where the U of -C q -U-C q is any one of O, S, SO 2 , or N(R 1 )(R 1 ), where each R 1 of N(R 1 )(R 1 ) independently hydrogen, and where R 1 , R 6 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 is H, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 is alkyl, and where R 1 , R 3 -R 4 , R 7 -R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 7 is H, and where R 1 , R 3 -R 4 , R 6 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 7 is fluoro, and where R 1 , R 3 -R 4 , R 6 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 7 is alkyl, and where R 1 , R 3 -R 4 , R 6 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 8 is H, and where R 1 , R 3 -R 4 , R 6 , R 7 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 8 is 2 H, and where R 1 , R 3 -R 4 , R 6 , R 7 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 8 is fluoro, and where R 1 , R 3 -R 4 , R 6 , R 7 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 8 is alkyl, and where R 1 , R 3 -R 4 , R 6 , R 7 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group comprises 4 carbon atoms, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group comprises 5 carbon atoms, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group comprises 6 carbon atoms, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group comprises 7 carbon atoms, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group comprises 9 carbon atoms, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group comprises 10 carbon atoms, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group is a fused cycloalkyl ring, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group is a fused heterocycloalkyl ring, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group is a fused aryl ring, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where R 6 and R 7 are bonded with an adjoining R group to form a fused group, where the fused group is a fused heteroaryl ring, and where R 1 , R 3 -R 4 , R 8 , Q, X, Z 1 , and W 1 are as defined.
  • a method of inhibiting the fatty acid binding protein FABP4 in a mammal which comprises administering an effective amount of a compound of Formula (I) to a mammal.
  • the subject is a human.
  • the compound according to Formula (I) is used in the prophylaxis or treatment of disorders acting on the fatty acid binding protein FABP4.
  • the disorders are: type 2 diabetes, hyperglycemia, Alzheimer’s disease, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, non-alcoholic steatohepatitis, asthma, multiple sclerosis, Alzheimer’s disease, other chronic inflammatory and autoimmune/inflammatory diseases, chronic heart disease, polycystic ovary syndrome, preeclampsia, or cancer.
  • composition comprising a compound according to Formula (I) as the active ingredient.
  • composition that further includes at least one additional active ingredient or a pharmaceutically acceptable carrier.
  • a method for the prophylaxis or treatment of disorders acting on the FABP4 which comprises administering an effective amount of a compound according to Formula (I) to a subject in need of treatment.
  • Diastereomeric mixtures may be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers may be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride, or formation of a mixture of diastereomeric salts), separating the diastereomers and converting (e.g., hydrolyzing or de-salting) the individual diastereomers to the corresponding pure enantiomers.
  • Enantiomers may also be separated by use of chiral HPLC column.
  • the chiral centers of compounds of the present invention may be designated as “R” or “S” as defined by the IUPAC 1974 Recommendations.
  • a “pharmaceutically acceptable salt” refers to a salt of a free acid or base of a compound of Formula I, II, or III that is non-toxic, is physiologically tolerable, is compatible with the pharmaceutical composition in which it is formulated, and is otherwise suitable for formulation and/or administration to a subject.
  • Reference to a compound herein is understood to include reference to a pharmaceutically acceptable salt of said compound unless otherwise indicated.
  • Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate (“mesylate”), ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (e.g., 1,1’-methylene-bis(2-hydroxy-3-naphthoate)) salts.
  • methanesulfonate (“mesylate”), ethane
  • a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion.
  • the counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
  • a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counterions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • alkali metal salts such as sodium, lithium, and potassium salts
  • alkaline earth metal salts such as calcium and magnesium salts
  • salts with organic bases for example, organic amines
  • organic amines such as dicyclohexylamines, t-butyl amines
  • salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen-containing groups may be quartemized with agents such as lower alkyl halides (e.g, methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g, dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g, decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g, benzyl and phenethyl bromides), and others.
  • lower alkyl halides e.g, methyl, ethyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates e.g, dimethyl, diethyl, and dibutyl sulfates
  • long chain halides e.g, decyl, lauryl, and stearyl chlorides
  • any compound described herein is intended to refer also to any unsolvated form, or a hydrate, solvate, or polymorph of such a compound, and mixtures thereof, even if such forms are not listed explicitly.
  • solvate means a physical association of a compound of the invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. As described herein, “solvate” encompasses both solution-phase and isolatable solvates. Suitable solvates include those formed with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • the solvent is water and the solvates are hydrates.
  • One or more compounds of the invention may optionally be converted to a solvate.
  • Methods for the preparation of solvates are generally known.
  • one group describes the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. See, M. Caira, et al., “Preparation and Crystal Characterization of a Polymorph, a Monohydrate, and an Ethyl Acetate Solvate of the Antifungal Fluconazole,” Journal of Pharmaceutical Sciences, 2004, 93(3), Pages 601-611, https://doi.org/10.1002/jps.10541.
  • a typical, non-limiting process involves dissolving the inventive compound in a suitable amounts of the solvent (organic solvent or water or a mixture thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
  • Analytical techniques such as, for example, infrared spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
  • the invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula I, II, or III, and treatment methods employing such pharmaceutically acceptable prodrugs.
  • prodrug means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula I).
  • a “pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise suitable for formulation and/or administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • prodrugs include pharmaceutically acceptable esters of the compounds of the invention, which are also considered to be part of the invention.
  • Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, Ci-4alkyl, Ci-4alkoxy, or amino); (2) sulfonate esters, such as alkyl- or aralkyl sulfonyl (for example, methanesulfonyl
  • the phosphate esters may be further esterified by, for example, a Ci-20 alcohol or reactive derivative thereof, or by a 2,3-di(C 6-24 )acyl glycerol. Additional discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
  • a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C 1 -C 8 )alkyl, (C 2 -C 12 )alkanoyloxymethyl, 1- (alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1 -methyl- l-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1 -methyl- 1- (alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)e
  • a group such as, for example, (C 1 -C 8 )alkyl, (
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C 1 -C 6 )alkanoyloxymethyl, l-((C 1 -C 6 )alkanoyloxy)ethyl, 1-methyl- l-((C 1 -C 6 )alkanoyloxy)ethyl, (C 1 -C 6 )alkoxycarbonyloxymethyl, N-(C 1 - C 6 )alkoxycarbonylaminom ethyl, succinoyl, (C 1 -C 6 )alkanoyl, a-amino(C 1 -C 4 )alkanyl, arylacyl and a-aminoacyl, or a-aminoacyl- a-aminoacyl, where each a-aminoacyl group is independently selected from the
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R”-carbonyl, R”0-carbonyl, NR”R'-carbonyl where R” and R' are each independently (C 1 -C 2 o)alkyl, (C3-C7) cycloalkyl, benzyl, or R”-carbonyl is a natural a-aminoacyl or natural a-aminoacyl, -C(OH)C(O)OY 1 wherein Y 1 is H, (C 1 -C 6 )alkyl or benzyl, -C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (C 1 -C 6 )alkyl, carboxy(C 1 -C 6 )alkyl, amino(Ci-C4)al
  • R a group such as, for example, R”-carbonyl,
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, n C, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, 36 C1, and 125 I, respectively.
  • Such isotopically labelled compounds are useful in metabolic studies (for example with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or U C labeled compound may be particularly suitable for PET or SPECT studies.
  • substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
  • Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent.
  • the embodiments of the present invention can also be a compound selected from the compounds listed below in Table 1.
  • Bicyclic beta-keto amide (3.5g, 14.285mmol) in 15mL of DMF was cooled to 0°C and triethylamine (2.48mL, 17.142mmol) was added and stirred for 5 min.
  • Comin’s reagent (3.78g, 17.142mmol) was added and the reaction mixture was stirred for 2h at room temperature. Reaction mixture was then poured into ice and pale yellow solid was formed which was filtered and dried to yield 3.0g of the desired product, as determined by LCMS and HNMR.
  • Tricyclic amide (0.2g, 0.606mmol) in toluene was added POBr 3 (0.52g, 1.818mmol) and stirred for 3h at 140 °C.
  • the reaction mixture was poured into ice and the aqueous layer was extract with EtOAc (x2). The organic layer was then dried over Na 2 SO 4 and concentrated. Purification by flash column chromatography gave the desired bromide product as determined by LCMS and HNMR.
  • Bicyclic beta-keto amide (3.5g, 14.285mmol) in 15mL of DMF was cooled to 0 °C and triethylamine (2.48mL, 17.142mmol) was added and stirred for 5 min.
  • Comin’s reagent (3.78g, 17.142mmol) was added and the reaction mixture was stirred for 2h at room temperature. Reaction mixture was then poured into ice and pale yellow solid was formed which was filtered and dried to yield 3.0g of the desired product, as determined by LCMS and HNMR.
  • Tricyclic amide (0.4g, 1.212mmol) in DMF (5mL) was cooled to 0°C and NaH (60% in Mineral Oil, 0.145g, 3.636mmol) was added portion wise and stirred for 30 minutes.
  • Bromo- methyl acetate (0.1303g, 1.818mmol) was added at 0 °C and the reaction mixture, after removal of ice bath, was stirred for 4h. Reaction was quenched with ice and organic layer was extracted with EtOAc (x2), dried over Na 2 SO 4 and concentrated by flash column chromatography gave the desired bromide product as determined by LCMS and HNMR.
  • Synthetic method C Representative example: 2- ⁇ [6-hexyl-4-(morpholin-4-yl)quinolin-2- yl](methyl)amino ⁇ acetic acid
  • Morpholino amide (O.lg, 0.3184mmol) in toluene (3mL) was added POBr 3 (0.273g, 0.955mmol) and stirred for 3h at 140°C.
  • the reaction mixture was poured into ice and the aqueous layer was extract with EtOAc (x2). The organic layer was then dried over Na 2 SO 4 and concentrated. Purification by flash column chromatography gave the desired bromide product as determined by LCMS and HNMR.
  • Morpholino bromide (0.08g, 0.212mmol) in DMSO (3mL) was added N-Methyl glycine methyl ester (0.145g, 1.063 mmol) and K2CO3 (0.090g, 0.636mmol). Reaction mixture was then stirred at 100°C for 16h before quenched with H 2 O. The mixture was acidified with IN HC1 to adjust the pH ⁇ 6 before being extracted with EtOAc (x2). Organic layer was dried over Na 2 SO 4 and concentrated before purification by reverse phase prep-HPLC to yield 2- ⁇ [6-hexyl-4- (morpholin-4-yl)quinolin-2-yl](methyl)amino ⁇ acetic acid as confirmed by H-NMR and LCMS.
  • Step 4 Synthesis of ethyl N-(6-bromo-4-phenylquinolin-2-yl)-N-methyl glycinate (Int # 1)
  • Step 3 Synthesis of 2-chloro-6-iodo-4-Phenylquinoline
  • 6-iodo-4-phenylquinolin-2-ol 29 g, 0.083 mol
  • POCl 3 200 mL
  • N, N-dimethyl aniline 29 mL, 1 Vol
  • the reaction mixture was concentrated under reduced pressure.
  • the resulting residue was poured on to ice- water (100 mL), and the precipitated solid was collected by filtration and dried under vacuum to afford 2-chloro-6-iodo-4-Phenylquinoline (27.3 g, 89.5%).
  • Step 4 Synthesis of N-(6-iodo-4-Phenylquinlin-2-yl)-N-methyl glycine (Int # 2)
  • Step 5 Synthesis of methyl N-(6-iodo-4-Phenylquinlin-2-yl)-N-methyl glycine (Int # 3)
  • Step-1 Synthesis of Methyl N-methyl-N-(4-phenyl-6-((trimethylsilyl)ethynyl) quinolin-2-yl) glycinate
  • Step-2 Synthesis of A-(6-ethynyl-4-phenylquinolin-2-yl)-N-methyl glycine
  • Step 1 Synthesis of ethyl 3-((4-hexylphenyl) amino)-2-methyl-3-oxopropanoate
  • Step 3 6-hexyl-3-methyl-2-oxo-l,2-dihydroquinolin-4-yl trifluoromethanesulfonate
  • DMF 4.0 mL
  • tri ethyl amine 0.4 mL, 2.895 mmol
  • N- Phenyl-bis(trifluoromethanesulfonimide) 413 mg, 1.16 mmol
  • Step 5 Synthesis of 2-bromo-6-hexyl-4-phenylquinoline (Intermediate # 5)
  • Step 1 Synthesis of N -(4-hexylphenyl)-3-oxo-3-phenylpropanamide
  • Step 3 Synthesis of 2-Bromo-6-hexyl-4-phenylquinoline (Int # 6 )
  • step-3 of scheme- 1 The process of this step was adopted from step-3 of scheme- 1.
  • the desired compound was obtained as pale- brown liquid (400 mg, 66%).
  • Step 3A Synthesis of 2-chloro-6-hexyl-4-phenylquinoline (Int-7)
  • Step 1 synthesis of ethyl (E)-N-methyl-N-(4-phenyl-6-styrylquinolin-2-yl) glycinate
  • Step-2 Synthesis of (E)-N-methyl -N-(4-phenyl-6-styrylquinolin-2-yl) glycine
  • ethyl (E)- N-methyl -N-(4-phenyl-6-styrylquinolin-2-yl) glycinate (0.035g, 0.082 mmol) in THF (2mL) and water (1 mL) at 0°C was added lithium hydroxide monohydrate (0.0017 g). The reaction mixture was slowly warmed to room temperature and stirred for 2 h.
  • Step-1 Synthesis of Ethyl N-methyl-N-(6-phenethyl-4-phenylquinolin-2-yl) glycinate
  • MeOH MeOH
  • Pd/C 10% Pd/C
  • Step 2 Synthesis of A-((2H-tetrazol-5-yl) methyl)-N-methyl-l-phenylmethanamine
  • 2-(benzyl(methyl)amino)acetonitrile 200 mg, 0.125 mmol
  • azidotributyl tin 625 mg, 1.88 mmol
  • T.L.C Eluent:30% EtOAc/Hexane, R.f: 0.30
  • Step 4 Synthesis of N-((2H-tetrazol-5-yl) methyl)-6-hexyl-N-methyl-4-phenylquinolin-2- amine
  • the crude compound was purified by column chromatography over silica gel (100- 200 mesh) using a solvent gradient of 30% EtOAc in Hexane as eluent to N-((2H-tetrazol -5-yl (methyl )-6-hexyl-N-methyl -4- phenylquinolin-2-amine (30 mg, 11%) as a pale yellow solid.
  • Step 3 Synthesis 6-hexyl-N-methyl-4-phenyl- N-((2H-tetrazol-5-yl)quinolin-2-amine
  • N-(6-hexyl-4-phenylquinolin-2-yl)-N-methylcyanamide 40 mg, 0.116 mmol
  • NaN 3 9 mg, 0.134 mmol
  • NH 4 Cl 13 mg, 0.232 mmol
  • the crude compound was purified by column chromatography over silica gel (100- 200 mesh) using a solvent gradient of 50% EtOAC in Hexane as eluent to afford 6-hexyl-N- methyl -4-phenyl -N-(2H-tetrazol-5-yl)quinolin-2-amine (12 mg, 26%) as an off-white solid.
  • Step 2 5-((6-hexyl-4-phenylquinolin-2-yl) methylene) thiazolidine-2,4-dione
  • the combined organic layer was dried over Na 2 SO 4 filtered and concentrated under reduced pressure to obtain crude compound.
  • the crude compound was purified by column chromatography over silica gel (100- 200 mesh) using a solvent gradient of 10% EtOAc in hexane as eluent to afford 5-((6-hexyl-4-phenylquinolin-2-yl) methylene) thiazolidine-2,4- dione (40 mg, 23%) as a beige solid.
  • the crude compound was purified by column chromatography over silica gel (100- 200 mesh) using a solvent gradient of 10% EtOAc in hexane as eluent to afford 5-((6-hexyl-4-phenylquinolin-2-yl) methyl) thiazolidine-2,4-dione) ( 30 mg, 75%) as a Pale-yellow solid.
  • Step 1 Synthesis of ethyl 2-((6-hexyl-4-phenylquinolin-2-yl)oxy)propanoate
  • Step 1 Synthesis of ethyl (E)-3-(6-hexyl-4-phenylquinolin-2-yl) but-2-enoate
  • step # 1 of example # 1 The process of this step was adopted from step # 1 of example # 1 to obtain the title compound (250 mg, 46 %) as a white solid.
  • Step 2 Synthesis of ethyl 3-(6-hexyl-4-phenylquinolin-2-yl) butanoate The process of this step was obtained from step-1 of Example # 2 to obtain the title compound (240 mg, 96%) as Grey color liquid.
  • Step 3 Synthesis of 3-(6-hexyl-4-phenylquinolin-2-yl) butanoic acid
  • the process of this step was obtained from step-2 of Example # 1 to obtain 3-(6-hexyl-4- phenylquinolin-2-yl) butanoic acid (143 mg, 64%) as a Pale-yellow thick liquid.
  • Step 1 Synthesis of N-(4-methoxyphenyl)-3-oxo-3-phenylpropanamide
  • 4-methoxy aniline 5 g, 40.60 mmol
  • xylene 50 mL
  • ethyl 3-oxo-3-phenylpropanoate 11.7 g, 60.90 mmol
  • EtO Ac/Hexane R.f: 0.6
  • Step 4 Synthesis of 2-chloro-4-phenylquinolin-6-ol
  • DCM dimethyl sulfoxide
  • BBr 3 3.3 mL, 3.33 mmol, 1M in DCM
  • the reaction mixture was allowed to room temperature for 4 h.
  • the reaction was quenched with ice-water (10 mL) and the product was extracted with DCM (3 X 15 mL) and washed with brine (1 X 20 mL).
  • Step 6 Synthesis of 2-((6-(benzyloxy)-4-phenylquinolin-2-yl) (methyl)amino) acetic acid
  • Step 1 Synthesis of methylN-methyl-N-(4-phenyl-6-(m-tolylethynyl) quinolin-2-yl) glycinate
  • the organic layer was dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to obtain the crude compound.
  • the crude compound was purified by prep-TLC and isolated N-methyl -A-(6-(3 -methyl phenethyl (-4- phenylquinolin-2-yl) glycine (40 mg, 21%) as off-white solid.
  • Step 1 Synthesis of ethyl l-(6-hexyl-4-phenylquinolin-2-yl)-5-oxopyrrolidine-3-carboxylate
  • a sealed tube was charged with 2-bromo-6-hexyl-4-phenylquinoline Int # 6 (1 g, 2.715 mmol), 4,4,5,5-tetramethyl-2-vinyl-l,3,2-dioxaborolane (0.501 g, 3.258 mmol) and sodium carbonate (0.862 g , 8.145 mmol) in DME (8 mL):H 2 0 ( 8 mL).
  • the reaction mixture was bubbled with nitrogen for 10 minutes and Pd (dppf)Cl 2 DCM (0.011 g, 0.135 mmol) was added to the reaction mixture, the sealed tube was tightened the cap and heated at 100°C for 12 h.
  • Step 2 Synthesis of ethyl 2-(6-hexyl-4-phenylquinolin-2-yl) cyclopropane-l-carboxylate
  • Step 3 Synthesis of 2-(6-hexyl-4-phenylquinolin-2-yl) cyclopropane-l-carboxylic acid
  • Step 4 Synthesis of (E)-N-methyl -4-phenyl-6-styryl-A-(lH-tetrazol-5-yl) quinolin-2-amine
  • Step 1 Synthesis of l-(3-bromophenyl) propan-l-ol
  • Step 2 Synthesis of l-bromo-3-propylbenzene
  • l-(3-bromophenyl) propan-l-ol 2.0 g, 9.345 mmol
  • DCM 20 mL
  • Et 3 SiH 22 mL, 140.175 mmol
  • BF 3 Et 2 0 4.6 mL, 37.38 mmol
  • Step 4 Synthesis methyl N-methyl -N-(4-phenyl-6-(3-propylphenyl) quinolin-2-yl) glycinate
  • the reaction mixture was degassed by bubbling nitrogen for 15 min and heated the sealed tube at 100°C for a period of 12 h. After completion of the reaction (monitored by T.L.C, Eluent: 10% EtOAc/Hexane, R.f 0.3). The reaction mixture was cooled to room temperature and filtered through a celite pad and washed with EtOAc (50 mL). The organic layer was washed with water (20 mL), dried over Na 2 SO 4 and concentrated under reduceed pressure to afford a crude product.
  • Step 5 Synthesis of N-methyl-N-(4-phenyl-6-(3-propylphenyl) quinolin-2-yl) glycine
  • Crude compound was purified by Prep HPLC, the relevant fractions containing the product were combined and kept for Lyophilization to affordN-methyl-N-(4-phenyl-6-(3-propylphenyl) quinolin-2-yl) glycine (18 mg, 10%) as pale yellow solid.
  • Step 1 Synthesis of methyl (E)-N-(6-(2-ethoxyvinyl)-4-phenylquinolin-2-yl)-N- methylglycinate
  • a sealed tube was charged with methyl N-(6-iodo-4-phenylquinolin-2-yl)-N-methyl glycinate Int # 3 (1 g, 2.314 mmol), (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (0.687 g, 3.471 mmol) and Aq 2M Sodium carbonate solution (2.314 mL, 4.628 mmol) in 1,4-dioxane (10 mL) .
  • the reaction mixture was bubbled with nitrogen for 10 minutes and then Pd(dppf)Cl 2 DCM (0.094 g, 0.115 mmol) was added to the reaction mixture , the selaed tube was tightened and heated at 100
  • Step 2 Synthesis of methyl N-methyl-N-(6-(2-oxoethyl)-4-phenylquinolin-2-yl) glycinate
  • Step 3 Synthesis of methyl N-methyl-N -(6-(2-morpholinoethyl)-4-phenylquinolin-2-yl) glycinate
  • Step 4 Synthesis of N-methyl-N-(6-(2-morpholinoethyl)-4-phenylquinolin-2-yl) glycine
  • Step 1 Synthesis of /V-(4-iodophenyl)-3-oxo-3-(pyridin-4-yl) propenamide
  • 4-iodoaniline 5 g, 22.828 mmol
  • Xylene 100 mL
  • ethyl 3-oxo-3-(pyridin-4-yl)propanoate 6.61 g, 34.242 mmol
  • Step 4 Synthesis of N-(6-iodo-4-(pyridin-4-yl) quinolin-2-yl)- N-methyl glycine
  • Step 6 Synthesis of methyl (E)-N-methyl -A-(6-(2-(pyridin-2-yl) vinyl)-4-(pyridin-4-yl) quinolin-2-yl) glycinate
  • a sealed tube was charged with methyl A-(6-iodo-4-(pyridin-4-yl)quinolin-2-yl)-N-methyl glycinate (300 mg, 0.692 mmol), 2-vinylpyridine (72.7 mg, 0.692 mmol) , triethylamine ( 0.287 mL, 2.078 mmol) and Tris(o-tolyl)phosphine (63 mg, 0.207 mmol ) in ACN (7 mL).
  • the reaction mixture was bubbled with nitrogen for 10 minutes and finally Pd (OAc)2 (15.5 mg, 0.069 mmol) was added to the reaction mixture and heated at 90°C for 12 h.
  • Step 7 Synthesis of methyl N-methyl-N-(6-(2-(pyridin-2-yl) ethyl)-4-(pyridin-4-yl) quinolin- 2-yl) glycinate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/US2021/014250 2020-01-20 2021-01-20 Novel cell metabolism modulating compounds and uses thereof WO2021150645A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202180018739.3A CN115209883A (zh) 2020-01-20 2021-01-20 新型细胞代谢调节化合物及其用途
US17/793,670 US20230183179A1 (en) 2020-01-20 2021-01-20 Novel cell metabolism modulating compounds and uses thereof
KR1020227028856A KR20220131536A (ko) 2020-01-20 2021-01-20 신규한 세포 대사 조절 화합물 및 이들의 용도
AU2021211437A AU2021211437A1 (en) 2020-01-20 2021-01-20 Novel cell metabolism modulating compounds and uses thereof
MX2022008938A MX2022008938A (es) 2020-01-20 2021-01-20 Nuevos compuestos moduladores del metabolismo celular y usos de los mismos.
BR112022014245A BR112022014245A2 (pt) 2020-01-20 2021-01-20 Compostos de modulação do metabolismo celular inovadores e usos dos mesmos
CA3165345A CA3165345A1 (en) 2020-01-20 2021-01-20 Novel cell metabolism modulating compounds and uses thereof
EP21744382.9A EP4093384A1 (en) 2020-01-20 2021-01-20 Novel cell metabolism modulating compounds and uses thereof
JP2022544103A JP2023518648A (ja) 2020-01-20 2021-01-20 細胞代謝を調節する新規化合物およびその使用
IL294786A IL294786A (en) 2020-01-20 2021-01-20 New compounds for regulating cell metabolism and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062963508P 2020-01-20 2020-01-20
US62/963,508 2020-01-20

Publications (1)

Publication Number Publication Date
WO2021150645A1 true WO2021150645A1 (en) 2021-07-29

Family

ID=76992718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/014250 WO2021150645A1 (en) 2020-01-20 2021-01-20 Novel cell metabolism modulating compounds and uses thereof

Country Status (11)

Country Link
US (1) US20230183179A1 (zh)
EP (1) EP4093384A1 (zh)
JP (1) JP2023518648A (zh)
KR (1) KR20220131536A (zh)
CN (1) CN115209883A (zh)
AU (1) AU2021211437A1 (zh)
BR (1) BR112022014245A2 (zh)
CA (1) CA3165345A1 (zh)
IL (1) IL294786A (zh)
MX (1) MX2022008938A (zh)
WO (1) WO2021150645A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168367A1 (en) * 2022-03-02 2023-09-07 Immunesensor Therapeutics, Inc. QUINOLINE cGAS ANTAGONIST COMPOUNDS
US11873291B2 (en) 2020-09-03 2024-01-16 Immunesensor Therapeutics, Inc. Quinoline cGAS antagonist compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541196A (en) * 1991-10-03 1996-07-30 Institut Francais De Recherche Scientifique Pour Le Developpment En Cooperation (Orstom) 2-substituted quinolines for the treatment of leishmaniasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101762704A (zh) * 2008-12-26 2010-06-30 上海裕隆生物科技有限公司 一种单克隆抗体制备方法及其应用
EP3676252B1 (en) * 2017-08-29 2023-11-29 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541196A (en) * 1991-10-03 1996-07-30 Institut Francais De Recherche Scientifique Pour Le Developpment En Cooperation (Orstom) 2-substituted quinolines for the treatment of leishmaniasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER A. LEPRE, JONATHAN M. MOORE, JEFFREY W. PENG: "Theory and applications of NMR-based screening in pharmaceutical research.", CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY, US, vol. 104, no. 8, 1 August 2004 (2004-08-01), US, pages 3641 - 3676, XP002679882, ISSN: 0009-2665, DOI: 10.1021/CR030409H *
DATABASE PUBCHEM Substance 14 March 2018 (2018-03-14), ANONYMOUS: "2-Ethylpyridine, 97%", XP055843371, retrieved from NCBI Database accession no. 24847096 *
KENNEY MC, MANSOOR S, GUPTA N, FALATOONZADEH P, KUPPERMANN BD: "2-ethylpyridine, a cigarette smoke component, causes mitochondrial damage in human retinal pigment epithelial cells in vitro", INDIAN JOUORNAL OF OPHTHALMOLOGY, ALL-INDIA OPHTHALMOLOGICAL SOCIETY, BOMBAY, IN, vol. 62, no. 1, 1 January 2014 (2014-01-01), IN, pages 16, XP055843370, ISSN: 0301-4738, DOI: 10.4103/0301-4738.126168 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11873291B2 (en) 2020-09-03 2024-01-16 Immunesensor Therapeutics, Inc. Quinoline cGAS antagonist compounds
WO2023168367A1 (en) * 2022-03-02 2023-09-07 Immunesensor Therapeutics, Inc. QUINOLINE cGAS ANTAGONIST COMPOUNDS

Also Published As

Publication number Publication date
MX2022008938A (es) 2022-10-18
EP4093384A1 (en) 2022-11-30
CA3165345A1 (en) 2021-07-29
JP2023518648A (ja) 2023-05-08
CN115209883A (zh) 2022-10-18
US20230183179A1 (en) 2023-06-15
IL294786A (en) 2022-09-01
BR112022014245A2 (pt) 2022-09-20
AU2021211437A1 (en) 2022-09-15
KR20220131536A (ko) 2022-09-28

Similar Documents

Publication Publication Date Title
CN109071498B (zh) 激酶抑制剂及其制备方法和用途
JP5820921B2 (ja) １，２−二置換複素環式化合物
KR20140041583A (ko) Ｌｒｒｋ2 키나제 활성의 억제제
EP3083631B1 (en) Wnt pathway modulators
WO2011085269A1 (en) Raf kinase inhibitors
WO2012119978A1 (en) Quinolinone derivatives
EP2531498B1 (en) Compounds and compositions as protein kinase inhibitors
AU2007243657A1 (en) Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists
EP2099789A1 (en) Inhibitors of hiv replication
JP7369139B2 (ja) Ｐｉ３キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体
WO2021150645A1 (en) Novel cell metabolism modulating compounds and uses thereof
JP2022521536A (ja) イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用
CN116568681A (zh) Sos1抑制剂、包含其的药物组合物及其用途
EP3992195A1 (en) Spiro (3,3'-isopropyl pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof
WO2022010948A1 (en) Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
CN110872285A (zh) 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物
CN111499591A (zh) RORγ调节剂
KR20200074177A (ko) 무스카린 m1 수용체 양성 알로스테릭 조절제로서 다환형 아미드
TW202024020A (zh) 治療神經退化性疾病之方法
AU2021297465A1 (en) Novel cell metabolism modulating compounds and uses thereof
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21744382

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022544103

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3165345

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022014245

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227028856

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021744382

Country of ref document: EP

Effective date: 20220822

ENP Entry into the national phase

Ref document number: 2021211437

Country of ref document: AU

Date of ref document: 20210120

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022014245

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220719

WWE Wipo information: entry into national phase

Ref document number: 522433353

Country of ref document: SA